Chardan Capital Reaffirms “Buy” Rating for Dyne Therapeutics (NASDAQ:DYN)

Chardan Capital reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report released on Monday morning, Benzinga reports. They currently have a $31.00 price objective on the stock. Chardan Capital also issued estimates for Dyne Therapeutics’ FY2025 earnings at ($2.94) EPS.

Several other analysts have also weighed in on DYN. Morgan Stanley started coverage on Dyne Therapeutics in a report on Tuesday, April 30th. They issued an overweight rating and a $40.00 price objective for the company. HC Wainwright reissued a buy rating and issued a $36.00 price target on shares of Dyne Therapeutics in a report on Friday, May 3rd. Oppenheimer reaffirmed an outperform rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, March 26th. Stifel Nicolaus increased their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a buy rating in a research note on Wednesday, March 6th. Finally, Piper Sandler lifted their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an overweight rating in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $37.75.

Dyne Therapeutics Trading Up 0.2 %

Dyne Therapeutics stock opened at $25.69 on Monday. Dyne Therapeutics has a 52 week low of $6.40 and a 52 week high of $30.27. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -6.47 and a beta of 1.00. The company’s 50-day moving average price is $26.49 and its two-hundred day moving average price is $18.88.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17). Research analysts expect that Dyne Therapeutics will post -3.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other news, insider Wildon Farwell sold 5,493 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $25.07, for a total value of $137,709.51. Following the completion of the sale, the insider now owns 163,503 shares of the company’s stock, valued at $4,099,020.21. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Wildon Farwell sold 5,493 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $25.07, for a total value of $137,709.51. Following the completion of the sale, the insider now directly owns 163,503 shares of the company’s stock, valued at $4,099,020.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jason P. Rhodes sold 177,906 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $23.89, for a total transaction of $4,250,174.34. Following the sale, the director now owns 7,148,211 shares of the company’s stock, valued at $170,770,760.79. The disclosure for this sale can be found here. Insiders have sold a total of 1,875,432 shares of company stock valued at $44,368,530 in the last three months. 20.77% of the stock is currently owned by company insiders.

Institutional Trading of Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. acquired a new position in Dyne Therapeutics in the 4th quarter worth about $4,988,000. Assenagon Asset Management S.A. grew its stake in shares of Dyne Therapeutics by 24.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 721,474 shares of the company’s stock valued at $6,464,000 after buying an additional 142,083 shares in the last quarter. Acuta Capital Partners LLC increased its holdings in Dyne Therapeutics by 100.7% in the third quarter. Acuta Capital Partners LLC now owns 146,500 shares of the company’s stock worth $1,313,000 after buying an additional 73,500 shares during the last quarter. TD Asset Management Inc bought a new position in Dyne Therapeutics during the third quarter valued at approximately $206,000. Finally, Profund Advisors LLC lifted its stake in Dyne Therapeutics by 9.8% in the third quarter. Profund Advisors LLC now owns 23,793 shares of the company’s stock valued at $213,000 after acquiring an additional 2,131 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.